Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives

被引:293
作者
Zhang, Rui Xue [1 ]
Wong, Ho Lun [2 ]
Xue, Hui Yi [2 ]
Eoh, June Young [2 ]
Wu, Xiao Yu [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, 144 Coll St, Toronto, ON M5S 2S2, Canada
[2] Temple Univ, Sch Pharm, 3304 North Broad St, Philadelphia, PA 19140 USA
关键词
Nanomedicine; Synergistic drug combinations; Cancer therapy; Strategies; Perspectives; METASTATIC BREAST-CANCER; OVERCOMING MULTIDRUG-RESISTANCE; ANTI-SURVIVIN SIRNA; CO-DELIVERY; IN-VITRO; POLYMERIC MICELLES; ANTICANCER DRUGS; SOLID TUMORS; MITOMYCIN-C; NANOPARTICLE FORMULATION;
D O I
10.1016/j.jconrel.2016.06.012
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nanomedicine of synergistic drug combinations has shown increasing significance in cancer therapy due to its promise in providing superior therapeutic benefits to the current drug combination therapy used in clinical practice. In this article, we will examine the rationale, principles, and advantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of nanocarriers for delivery of a variety of combinations of different classes of anticancer agents including small molecule drugs and biologics, and discuss the challenges and future perspectives of the nanocarrier-based combination therapy. The goal of this review is to provide better understanding of this increasingly important new paradigm of cancer treatment and key considerations for rational design of nanomedicine of synergistic drug combinations for cancer therapy. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:489 / 503
页数:15
相关论文
共 157 条
[1]  
AACR, 2015, NEW ANT DRUG CONJ SH
[2]   Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer:: A Spanish breast cancer research group (GEICAM-9903) phase III study [J].
Alba, E ;
Martín, M ;
Ramos, M ;
Adrover, E ;
Balil, A ;
Jara, C ;
Barnadas, A ;
Fernández-Aramburo, A ;
Sánchez-Rovira, P ;
Amenedo, M ;
Casado, A .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2587-2593
[4]  
[Anonymous], 2015, Global cancer facts figures, V3rd
[5]  
[Anonymous], 2016, CANC FACTS FIG 2016
[6]  
[Anonymous], 2001, COMB CHEM REG TYP CA
[7]  
Batist G, 2008, J CLIN ONCOL, V26
[8]   Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors [J].
Batist, Gerald ;
Gelmon, Karen A. ;
Chi, Kim N. ;
Miller, Wilson H., Jr. ;
Chia, Stephen K. L. ;
Mayer, Lawrence D. ;
Swenson, Christine E. ;
Janoff, Andrew S. ;
Louie, Arthur C. .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :692-700
[9]   P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives [J].
Binkhathlan, Ziyad ;
Lavasanifar, Afsaneh .
CURRENT CANCER DRUG TARGETS, 2013, 13 (03) :326-346
[10]   Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway [J].
Blanco, Elvin ;
Sangai, Takafumi ;
Wu, Suhong ;
Hsiao, Angela ;
Ruiz-Esparza, Guillermo U. ;
Gonzalez-Delgado, Carlos A. ;
Cara, Francisca E. ;
Granados-Principal, Sergio ;
Evans, Kurt W. ;
Akcakanat, Argun ;
Wang, Ying ;
Do, Kim-Anh ;
Meric-Bernstam, Funda ;
Ferrari, Mauro .
MOLECULAR THERAPY, 2014, 22 (07) :1310-1319